![金银双杀:美国PMI引爆市场,分析师深度剖析未来走势](https://i-invdn-com.investing.com/news/external-images-thumbnails/picce486b8b2bfbe6661f75bb55928dc9ee.png)
注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
名称 | 标题 | 任期 | 至 |
---|---|---|---|
Jason A. Kritzer | Vice President | 2016 | now |
背景介紹 | Mr. Kritzer is a Vice President of Eaton Vance. Prior to joining Eaton Vance in 2012, Mr. Kritzer was a director and equity analyst at BlackRock , Inc. covering the healthcare sector since 2006. | ||
Samantha Pandolfi | Vice President | 2016 | now |
背景介紹 | Ms. Pandolfi is a Vice President of EVAIL. Prior to joining EVAIL, Ms. Pandolfi held similar positions at EVMI. Prior to joining EVMI as a Vice President in November 2015, Ms. Pandolfi was a Portfolio Manager and Research Analyst with Goldman Sachs Asset Management over her fifteen year tenure (2000-2015). | ||
Sven H. Borho | Founding General Partner | 2005 | 2016 |
背景介紹 | Sven H. Borho, CFA, is a founding General Partner of OrbiMed. Mr. Borho is a portfolio manager for OrbiMed’s public equity funds and he heads the firm’s trading efforts. He started his career in 1991 when he joined Mehta and Isaly as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. In 1993, Mr. Borho became portfolio manager to investment funds under management. Mr. Borho studied business administration at Bayreuth University in Germany and received a M. Sc. (Econ.) from The London School of Economics; he is a citizen of both Germany and Sweden. | ||
Richard D. Klemm | Biotechnology Analyst | 2005 | 2016 |
背景介紹 | Klemm joined OrbiMed in 2000 as a biotechnology analyst. Klemm has earned the right to use the Chartered Financial Analyst designation. | ||
Geoffrey C. Hsu | Biotechnology Analyst | 2005 | 2016 |
背景介紹 | Hsu joined OrbiMed in 2002 as a biotechnology analyst. Prior to joining OrbiMed, he worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. Hsu has earned the right to use the Chartered Financial Analyst designation. | ||
Trevor M. Polischuk | Analyst | 2005 | 2016 |
背景介紹 | Polischuk joined OrbiMed in 2003 as an analyst covering the major global pharmaceutical industry. Previously, he worked at Lehman Brothers as a senior research analyst covering the U.S. pharmaceutical industry. | ||
Samuel David Isaly | Portfolio Manager | 1985 | 2016 |
背景介紹 | Samuel D. Isaly founded Exome in 2018 and is the Managing Member. Mr. Isaly is one of the world’s most recognized healthcare fund managers and has been active in global healthcare investing and analysis since 1968 when he joined Chase Manhattan Bank in New York. During his career, Mr. Isaly has been a pharmaceutical analyst with Chase Manhattan Bank, Merrill Lynch, Legg Mason, and S.G. Warburg. Isaly was a portfolio manager with OrbiMed Advisors. Previously, he was a president and partner with Mehta and Isaly Asset Management. From 1986 to 1989, he was a senior vice president with S.G. Warburg & Company. He also spent more than three years as a partner with Gramercy Associates, one and a half years as a vice president with Merrill Lynch & Company, and two years as a vice president with Chase Manhattan Bank. | ||
Bernard Graham | - | 1985 | 1989 |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核